AIMS To evaluate the relationship between activated partial thromboplastin time (aPTT) and clinical outcomes in the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO-V) trial comparing standard-dose reteplase to half-dose reteplase and abciximab. METHODS AND RESULTS We analysed data on 11,420 patients receiving unfractionated heparin. Peak aPTT levels recorded during the hosp...

BACKGROUND In patients receiving heparin infusions, variations in specimen collection technique may contribute to inaccurate measurements of activated partial thromboplastin time (aPTT). OBJECTIVES To determine if there is a difference in aPTT results between specimens collected from a central venous access device (CVAD) compared with venipuncture in patients receiving heparin infusions. ME...

The lupus inhibitor is an autoantibody with anticoagulant properties, and is found in a high proportion of patients with 'systemic lupus eryth-ematosus (SLE) as well as in patients with a wide variety of other disorders.'3 It is characterised by prolongation of phospholipid dependent coagulation tests due to its binding to phosphodiester linkages on the phospholipid portion of the factor Xa, fa...

Background: Coagulation, also known as blood clotting, is the process by which convert from a liquid to gel, forming clot. It referred haemostasis, stopping of loss damaged vessel, followed repair.
 Material and methods: This was cross sectional study conducted at albawasla medical laboratory, Khartoum, Sudan during period August November, 2021 evaluate effect time hemolysis on prothrombin...

BACKGROUND After kidney transplantation, a renal biopsy may be needed to elucidate the reasons for lack of graft function. If the activated partial thromboplastin time (aPTT) is prolonged, the biopsy will often be postponed, as increased risk of bleeding must be expected. However, aPTT prolongation is not always due to lack of coagulation factors, but can be due to the presence of lupus anticoa...

BACKGROUND A reduced sensitivity for activated protein C (APC) is associated with an increased risk of venous thrombosis even in the absence of the factor (F)V Leiden mutation. This risk has been demonstrated with two APC sensitivity tests, which quantify the effects of APC on the activated partial thromboplastin time (APTT) and the endogenous thrombin potential (ETP), respectively. OBJECTIVE...

The goal of heparin therapy in deep vein thrombosis is to prevent thrombus extension. The relationship between thrombus extension and the results of coagulation tests used to monitor heparin therapy is unclear. To explore this relationship, we studied the effect of several heparin regimens on the accretion of indium-111-labeled platelets on fresh venous thrombi, as detected by gamma imaging, an...

In determining heparin one has the choice to test a specific activity, such as the decay constant of thrombin or factor Xa on a global test such as the aPTT. The best test would be a global test that directly reflects the only important global effect, to wit antithrombotic efficiency. Such a test does not yet exist. We propose that the thrombin potential, i.e. the time concentration integral of...